Stockreport

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at ...

DBV Technologies S.A. - American Depositary Shares  (DBVT) 
US:NASDAQ Investor Relations: dbv-technologies.com/en/investor-relations
PDF DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Trea [Read more]